scholarly journals Intrapleural Administration of Fibrinolytic Enzymes as an Adjunct Therapy of Parapneumonic Purulent Pleural Exudation: Does it Affect Outcome?

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Saber Ahmed ◽  
Adel Waleed
Keyword(s):  
Adjunct Therapy ◽  
Fibrinolytic Enzymes ◽  
Intrapleural Administration

Tridegin, a Novel Peptidic Inhibitor of Factor XIIIa from the Leech, Haementeria ghilianii, Enhances Fibrinolysis In Vitro

1997 ◽  
Vol 77 (05) ◽  
pp. 0959-0963 ◽  
Author(s):  
Lisa Seale ◽  
Sarah Finney ◽  
Roy T Sawyer ◽  
Robert B Wallis
Keyword(s):  
Potent Inhibitor ◽  
Platelet Rich Plasma ◽  
Factor Xiiia ◽  
Cross Linking ◽  
Fibrinolytic Enzymes ◽  
Small Polypeptide ◽  
Tissue Plasminogen ◽  
Protein Cross Linking

SummaryTridegin is a potent inhibitor of factor Xllla from the leech, Haementeria ghilianii, which inhibits protein cross-linking. It modifies plasmin-mediated fibrin degradation as shown by the absence of D-dimer and approximately halves the time for fibrinolysis. Plasma clots formed in the presence of Tridegin lyse more rapidly when either streptokinase, tissue plasminogen activator or hementin is added 2 h after clot formation. The effect of Tridegin is markedly increased if clots are formed from platelet-rich plasma. Platelet-rich plasma clots are lysed much more slowly by the fibrinolytic enzymes used and if Tridegin is present, the rate of lysis returns almost to that of platelet- free clots. These studies indicate the important role of platelets in conferring resistance to commonly used fibrinolytic enzymes and suggest that protein cross-linking is an important step in this effect. Moreover they indicate that Tridegin, a small polypeptide, may have potential as an adjunct to thrombolytic therapy.

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1179-P ◽  
Author(s):  
THOMAS DANNE ◽  
BERTRAND CARIOU ◽  
JOHN B. BUSE ◽  
SATISH K. GARG ◽  
JULIO ROSENSTOCK ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Adjunct Therapy ◽  
Time In Range

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 212-OR ◽  
Author(s):  
JOHN B. BUSE ◽  
SATISH K. GARG ◽  
JULIO ROSENSTOCK ◽  
TIMOTHY S. BAILEY ◽  
PHILLIP L. BANKS ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sglt2 Inhibitor ◽  
Efficacy And Safety ◽  
Adjunct Therapy

scholarly journals Alternative dosing of omalizumab as an adjunct therapy during multiallergen oral immunotherapy in food allergic patients

2019 ◽  
Vol 143 (2) ◽  
pp. AB245
Author(s):  
Sayantani B. Sindher ◽  
Andrew J. Long ◽  
Natasha Purington ◽  
Divya Kumar ◽  
Alexandra Scheiber ◽  
...  
Keyword(s):  
Oral Immunotherapy ◽  
Adjunct Therapy

scholarly journals Zinc supplementation as an adjunct therapy for COVID‐19: challenges and opportunities

2021 ◽  
Author(s):  
Vidyasagar Chinni ◽  
Hanna El‐Khoury ◽  
Marlon Perera ◽  
Rinaldo Bellomo ◽  
Daryl Jones ◽  
...  
Keyword(s):  
Zinc Supplementation ◽  
Adjunct Therapy ◽  
Challenges And Opportunities

scholarly journals Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)

2017 ◽  
Vol 28 ◽  
pp. v122 ◽  
Author(s):  
S. Danson ◽  
P. Woll ◽  
J. Edwards ◽  
K. Blyth ◽  
P. Fisher ◽  
...  
Keyword(s):  
Phase I ◽  
Intrapleural Administration
Sign in / Sign up

Export Citation Format

Share Document